Serbia's Galenika seeking Indian interest?
This article was originally published in Scrip
It looks like plans to potentially privatize the state-owned Serbian firm, Galenika Pharmaceuticals, are beginning to gather some pace with efforts apparently underway to elicit Indian interest.
You may also be interested in...
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.
Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.